Tirzepatide is a first-in-class dual GLP-1 and GIP receptor agonist approved for type 2 diabetes (as Mounjaro) and obesity (as Zepbound). It's a weekly injection that improves blood sugar control and produces significant weight loss by activating two incretin hormone receptors.

How does tirzepatide compare to semaglutide?

Head-to-head trials show tirzepatide produces greater weight loss (12.4kg vs 6.2kg) and better glucose control than semaglutide 1mg. At maximum doses, tirzepatide achieves ~22% weight loss vs ~17% for semaglutide. However, semaglutide has more cardiovascular outcomes data.

Is tirzepatide approved in the UK?

Yes. Mounjaro (tirzepatide for diabetes) received MHRA approval in 2023. Zepbound (for weight management) approval is pending or recently approved. Both are prescription-only medicines requiring medical supervision.

What are the side effects of tirzepatide?

Common side effects include nausea, diarrhoea, vomiting, and constipation—though these may be somewhat milder than pure GLP-1 agonists. Hair loss has been reported in weight loss trials, likely due to rapid weight loss. Rare risks include pancreatitis and gallbladder problems.

How much weight can I lose on tirzepatide?

Clinical trials show average weight loss of 20-22% at the highest doses (15mg). About 63% of participants lost 20% or more of their body weight. Results vary individually and depend on dose, adherence, diet, and physical activity.

Can I buy tirzepatide without a prescription?

No. Tirzepatide is a prescription-only medicine. Purchasing from unregulated sources is dangerous and may result in counterfeit, contaminated, or incorrectly dosed products. Always obtain through legitimate healthcare providers.

What is the difference between Mounjaro and Zepbound?

Both contain tirzepatide. Mounjaro is approved for type 2 diabetes, while Zepbound is approved specifically for weight management. The medication is identical; the difference is the approved indication and potentially insurance coverage.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-02-02

Share:X Post LinkedIn

GLP-1 Agonists•Updated 2026-02-02•6 min read

What Is Tirzepatide? Benefits, Research & Safety

Q: Why does tirzepatide cause more weight loss than semaglutide?

Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide only activates GLP-1. The dual mechanism appears to produce synergistic effects on appetite suppression and metabolism. The exact mechanisms are still being researched.

A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.

Also known as:

Mounjaro

Zepbound

LY3298176

Educational Content Only: This page provides research-based information for educational purposes. Tirzepatide is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.

Quick Facts

Overview

Tirzepatide represents the next evolution in incretin-based therapies, being the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist to achieve regulatory approval. Developed by Eli Lilly, it is marketed as Mounjaro® (for diabetes) and Zepbound® (for weight management). By activating both GIP and GLP-1 receptors, tirzepatide produces greater metabolic effects than GLP-1 agonists alone. The SURMOUNT trials demonstrated unprecedented weight loss of up to 22.5%—results approaching those of bariatric surgery without surgical intervention. The molecule consists of a 39-amino acid peptide engineered to activate both incretin receptors. A fatty acid modification enables once-weekly dosing, similar to semaglutide. The dual mechanism appears to produce synergistic effects on glucose control, appetite suppression, and body composition. Tirzepatide has been described as a paradigm shift in obesity treatment, prompting discussions about obesity as a treatable chronic disease rather than a lifestyle failure. Its success has accelerated development of even more potent multi-agonist compounds. **Regulatory Status:** Tirzepatide is a prescription-only medicine approved by the FDA and EMA. It should only be obtained through legitimate healthcare channels.

Discovery & History

Tirzepatide's development arose from understanding that GIP and GLP-1, the two main incretin hormones, might have complementary effects when activated together. **Scientific Background:** • **GIP and GLP-1:** Both hormones are released from the gut after eating and enhance insulin secretion. However, GIP's role in obesity was initially controversial—early studies suggested GIP might promote fat storage. • **Reconsidering GIP:** Research by Eli Lilly and academic groups revealed that GIP receptor activation in the brain might reduce food intake, contrary to earlier assumptions about its fat-promoting effects. **Development Timeline:** • **2016:** Eli Lilly begins Phase 1 trials of LY3298176 • **2018:** Phase 2 results show superior efficacy to dulaglutide and semaglutide • **2020-2021:** SURPASS trials for diabetes show superior glucose control • **2021-2022:** SURMOUNT trials for obesity show unprecedented weight loss • **May 2022:** FDA approval of Mounjaro for type 2 diabetes • **September 2022:** EMA approval for Mounjaro • **November 2023:** FDA approval of Zepbound for weight management • **2024:** MHRA approval and UK availability begins The discovery that dual agonism produced greater effects than either receptor alone was somewhat surprising and has driven development of triple agonists like retatrutide.

Mechanism of Action

Tirzepatide uniquely activates two incretin receptors, producing complementary metabolic effects: **GLP-1 Receptor Activation:** Similar to semaglutide, tirzepatide activates GLP-1 receptors to: - Enhance glucose-dependent insulin secretion - Suppress glucagon release - Slow gastric emptying - Reduce appetite through hypothalamic signalling **GIP Receptor Activation:** The GIP component adds distinct benefits: - Additional insulin secretion enhancement - Potential improvements in beta cell function - Central nervous system effects on appetite (distinct from GLP-1) - Possible effects on fat metabolism and distribution **Synergistic Effects:** The dual mechanism appears to produce more than additive benefits: - Greater weight loss than GLP-1 agonists alone - Improved glucose control beyond single-agonist therapies - Potentially better tolerability (nausea may be reduced) - Enhanced effects on body composition **Molecular Design:** Tirzepatide is a 39-amino acid peptide based on the native GIP sequence but engineered to also activate GLP-1 receptors. Key features include: - C20 fatty diacid attached via linker, enabling albumin binding - Half-life of approximately 5 days allowing weekly dosing - Relative GIP:GLP-1 activation ratio of approximately 5:1 **Adipose Tissue Effects:** Emerging research suggests tirzepatide may have direct effects on fat tissue: - Improved insulin sensitivity in adipocytes - Enhanced fat oxidation - Potential preferential loss of visceral fat - Possible effects on adipokine secretion [Diagram Placeholder: Dual receptor signalling showing GIP and GLP-1 pathways, including pancreatic, central nervous system, and adipose tissue effects]

[Molecular Structure Diagram Placeholder]

Researched Benefits

Based on preclinical and clinical research findings:

1
Weight loss of 20-22% in clinical trials—approaching bariatric surgery results
2
Superior glycaemic control with HbA1c reductions of 2.0-2.5%
3
Significant reductions in liver fat (important for NAFLD/NASH)
4
Improvements in blood pressure and lipid profiles
5
High rates of diabetes remission (HbA1c <6.5% without medication)
6
Reduced waist circumference and preferential visceral fat loss
7
Improvements in markers of inflammation
8
Better physical function and quality of life measures
9
Potential cardiovascular benefits (outcomes trials ongoing)

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Mounjaro/Zepbound: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg weekly
Frequency	Once weekly subcutaneous injection
Duration	Ongoing treatment; dose escalation over 20+ weeks
Notes	Tirzepatide is a prescription medication requiring medical supervision. Slow dose escalation is critical for tolerability. The highest doses (12.5mg, 15mg) are required for maximum weight loss but carry increased GI side effect risk. This is NOT a research peptide—obtain only through legitimate healthcare providers.

Administration Routes

Routes studied in research settings (educational only):

Subcutaneous injection (Mounjaro, Zepbound)—once weekly
Oral formulation in development

Half-Life	Stability
Approximately 5 days (120 hours)	Refrigerate at 2-8°C before first use; can be kept at room temperature (below 30°C) for up to 21 days; protect from light

Safety Profile & Known Risks

Commonly Reported Side Effects

Nausea (may be less severe than with pure GLP-1 agonists)
Diarrhoea
Vomiting
Constipation
Abdominal pain
Decreased appetite
Dyspepsia (indigestion)
Injection site reactions
Fatigue
Hair loss (reported in weight loss trials—likely related to rapid weight loss)

Rare Risks & Concerns

Pancreatitis
Gallbladder disease and gallstones
Hypoglycaemia (especially with insulin or sulfonylureas)
Acute kidney injury (secondary to dehydration)
Allergic reactions
Thyroid C-cell tumours (rodent finding; clinical significance unknown)
Intestinal obstruction (rare, in patients with GI disease)

Contraindications

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2
Known hypersensitivity to tirzepatide
Pregnancy and breastfeeding
Type 1 diabetes
History of pancreatitis
Severe gastrointestinal disease

UK & EU Regulatory Context

🇬🇧 United Kingdom

Mounjaro approved by MHRA for type 2 diabetes (2023). Zepbound for weight management under review/approved. Prescription-only medicine.

🇪🇺 European Union

Mounjaro approved by EMA (September 2022) for type 2 diabetes. Weight management approval ongoing.

Tirzepatide is a prescription-only medication. It is NOT a research peptide and should only be obtained through legitimate healthcare channels. Counterfeit products are a significant concern—only use verified pharmacies.

Clinical Studies Summary

SURMOUNT-1: Tirzepatide for Weight Management

Landmark obesity trial showing 15mg tirzepatide produced 22.5% mean weight loss vs 2.4% placebo over 72 weeks. 63% of participants lost ≥20% body weight.

N Engl J Med. 2022;387:205-216View on PubMed

SURPASS-2: Tirzepatide vs Semaglutide

Head-to-head comparison showing tirzepatide 15mg superior to semaglutide 1mg for glucose control (HbA1c reduction 2.46% vs 1.86%) and weight loss (12.4kg vs 6.2kg).

N Engl J Med. 2021;385:503-515View on PubMed

SURMOUNT-3: After Lifestyle Intervention

Tirzepatide after initial 12-week intensive lifestyle intervention showed total weight loss of 26.6% from pre-lifestyle baseline.

Nat Med. 2023;29:2909-2918View on PubMed

SURMOUNT-4: Weight Maintenance

Continuing tirzepatide after initial weight loss maintained weight reduction, while switching to placebo resulted in regain of approximately half the lost weight.

JAMA. 2024;331:38-48View on PubMed

Looking for Tirzepatide?

Source research-grade Tirzepatide from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Related Research Guides

Peptides for Fat Loss

Read guide

Related Peptides

Semaglutide

A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.

Learn more

Liraglutide

An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.

Learn more

GLP-1

A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.

Learn more

GLP-1

A natural incretin hormone that regulates blood glucose and appetite, the basis for revolutionary diabetes and obesity medications.

Learn more

Semaglutide

A once-weekly GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, representing a breakthrough in metabolic medicine with average weight loss of 15-17% in clinical trials.

Learn more

Retatrutide

An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, showing unprecedented weight loss of up to 24% in Phase 2 trials—potentially the most potent obesity treatment in development.

Learn more

Explore More Peptides

Browse our comprehensive database of research-backed peptide profiles.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-02-02

Share:X Post LinkedIn

GLP-1 Agonists•Updated 2026-02-02•6 min read

What Is Tirzepatide? Benefits, Research & Safety

A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.

Also known as:

Mounjaro

Zepbound

LY3298176

Quick Facts

Overview

Discovery & History

Mechanism of Action

[Molecular Structure Diagram Placeholder]

Researched Benefits

Based on preclinical and clinical research findings:

1
Weight loss of 20-22% in clinical trials—approaching bariatric surgery results
2
Superior glycaemic control with HbA1c reductions of 2.0-2.5%
3
Significant reductions in liver fat (important for NAFLD/NASH)
4
Improvements in blood pressure and lipid profiles
5
High rates of diabetes remission (HbA1c <6.5% without medication)
6
Reduced waist circumference and preferential visceral fat loss
7
Improvements in markers of inflammation
8
Better physical function and quality of life measures
9
Potential cardiovascular benefits (outcomes trials ongoing)

Theoretical Dosing & Protocols

Theoretical Dosage	Mounjaro/Zepbound: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg weekly
Frequency	Once weekly subcutaneous injection
Duration	Ongoing treatment; dose escalation over 20+ weeks
Notes	Tirzepatide is a prescription medication requiring medical supervision. Slow dose escalation is critical for tolerability. The highest doses (12.5mg, 15mg) are required for maximum weight loss but carry increased GI side effect risk. This is NOT a research peptide—obtain only through legitimate healthcare providers.

Administration Routes

Routes studied in research settings (educational only):

Subcutaneous injection (Mounjaro, Zepbound)—once weekly
Oral formulation in development

Half-Life	Stability
Approximately 5 days (120 hours)	Refrigerate at 2-8°C before first use; can be kept at room temperature (below 30°C) for up to 21 days; protect from light

Safety Profile & Known Risks

Commonly Reported Side Effects

Nausea (may be less severe than with pure GLP-1 agonists)
Diarrhoea
Vomiting
Constipation
Abdominal pain
Decreased appetite
Dyspepsia (indigestion)
Injection site reactions
Fatigue
Hair loss (reported in weight loss trials—likely related to rapid weight loss)

Rare Risks & Concerns

Pancreatitis
Gallbladder disease and gallstones
Hypoglycaemia (especially with insulin or sulfonylureas)
Acute kidney injury (secondary to dehydration)
Allergic reactions
Thyroid C-cell tumours (rodent finding; clinical significance unknown)
Intestinal obstruction (rare, in patients with GI disease)

Contraindications

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2
Known hypersensitivity to tirzepatide
Pregnancy and breastfeeding
Type 1 diabetes
History of pancreatitis
Severe gastrointestinal disease

UK & EU Regulatory Context

🇬🇧 United Kingdom

Mounjaro approved by MHRA for type 2 diabetes (2023). Zepbound for weight management under review/approved. Prescription-only medicine.

🇪🇺 European Union

Mounjaro approved by EMA (September 2022) for type 2 diabetes. Weight management approval ongoing.

Clinical Studies Summary

SURMOUNT-1: Tirzepatide for Weight Management

Landmark obesity trial showing 15mg tirzepatide produced 22.5% mean weight loss vs 2.4% placebo over 72 weeks. 63% of participants lost ≥20% body weight.

N Engl J Med. 2022;387:205-216View on PubMed

SURPASS-2: Tirzepatide vs Semaglutide

Head-to-head comparison showing tirzepatide 15mg superior to semaglutide 1mg for glucose control (HbA1c reduction 2.46% vs 1.86%) and weight loss (12.4kg vs 6.2kg).

N Engl J Med. 2021;385:503-515View on PubMed

SURMOUNT-3: After Lifestyle Intervention

Tirzepatide after initial 12-week intensive lifestyle intervention showed total weight loss of 26.6% from pre-lifestyle baseline.

Nat Med. 2023;29:2909-2918View on PubMed

SURMOUNT-4: Weight Maintenance

Continuing tirzepatide after initial weight loss maintained weight reduction, while switching to placebo resulted in regain of approximately half the lost weight.

JAMA. 2024;331:38-48View on PubMed

Looking for Tirzepatide?

Source research-grade Tirzepatide from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Related Research Guides

Peptides for Fat Loss

Read guide

Explore More Peptides

Browse our comprehensive database of research-backed peptide profiles.

Quick Facts

Overview

Discovery & History

Mechanism of Action

Researched Benefits

Theoretical Dosing & Protocols

Administration Routes

Safety Profile & Known Risks

Commonly Reported Side Effects

Rare Risks & Concerns

Contraindications

UK & EU Regulatory Context

🇬🇧 United Kingdom

🇪🇺 European Union

Clinical Studies Summary

SURMOUNT-1: Tirzepatide for Weight Management

SURPASS-2: Tirzepatide vs Semaglutide

SURMOUNT-3: After Lifestyle Intervention

SURMOUNT-4: Weight Maintenance

Looking for Tirzepatide?

Frequently Asked Questions